The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Open accessAbstract
MicroRNA-34 (miR-34) has been reported to be dysregulated in various human cancers and regarded as a tumor suppressive microRNA because of its synergistic effect with the well-known tumor suppressor p53. Along with the application of MRX34, the first tumor-targeted microRNA drug which based on miR-34a mimics, on phase I clinical trial (NCT01829971), the significance of miR-34 is increasingly recognized. miR-34 plays a crucial role on repressing tumor progression by involving in epithelial-mesenchymal transition (EMT) via EMT- transcription factors, p53 and some important signal pathways. Not only that, numerous preclinical researches revealed the giant potential of miR-34a on cancer therapy through diversiform nano-scaled delivery systems. Here, we provide an overview about the function of miR-34 in various cancers and the mechanism of miR-34 in tumor-associated EMT. Furthermore, its potential role as a microRNA therapeutic candidate is also discussed. Notwithstanding some obstacles existed, the extensive application prospect of miR-34 on oncotherapy cannot be neglected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in Acute Myeloid Leukemia Cells
Liu, L., Ren, W., & Chen, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475277 · Cited by 100
RetractedWang, Y., & Wang, L. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2397-z · Cited by 59
RetractedWen, X., Han, X., Wang, Y., Wang, S., Shen, M., Zhang, Z.-F., Fan, S., Shan, Q., Wang, L., Li, M., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26498 · Cited by 52
RetractedLiu, G. (2025) · American Journal of Translational Research · doi:10.62347/jvrm8589 · Cited by 31
RetractedXi, L., Zhang, Y., Kong, S., & Liang, W. (2018) · Bioscience Reports · doi:10.1042/bsr20180078 · Cited by 27
RetractedZhu, L., Xue, F., Xu, X., Xu, J., Hu, S., Liu, S., Cui, Y., & Gao, C. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27204 · Cited by 22
RetractedProceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,893
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“In addition, some other unexpected side effects may come up, such as the accumulation of therapeutic miRNAs at healthy tissues because of the conjunction of serum proteins on the surface of nano-vectors, the breakdown of nanoparticles on the account of the shearing stress which from the flowing blood, the unsuccessful…”
BackgroundMicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“This novel therapeutic approach via miRNA mimics or antimiRs to modulate miRNA expression and activity in vivo [83].”
Background
Cited by
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Metadata
- Authors
- Zhang, L., Liao, Y., & Tang, L.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2019-02-04
- Volume
- 38
- Issue
- 1
- Pages
- 53-53
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2921638830
- Cited by
- 510
- References
- 125
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. https://app.cochat.ai/papers/10.1186/s13046-019-1059-5
- The paper
- Zhang, L., Liao, Y., & Tang, L. (2019). MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1059-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.